---
title: "花旗银行维持对福泰制药（VRTX）的买入评级"
description: "Meacham 涉及医疗保健行业，关注的股票包括礼来公司（Eli Lilly & Co）、安进（Amgen）和福泰制药（Vertex Pharmaceuticals）。根据 TipRanks 的数据，Meacham 推荐股票的平均回报率为 4.2%，成功率为 55.14%。福泰制药的分析师共识为适度买入，价格目标共识为 488.86 美元，较当前水平有 19.88% 的上涨空间。在 10 月 9 "
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/260882169.md"
published_at: "2025-10-13T10:55:58.000Z"
---

# 花旗银行维持对福泰制药（VRTX）的买入评级

> Meacham 涉及医疗保健行业，关注的股票包括礼来公司（Eli Lilly & Co）、安进（Amgen）和福泰制药（Vertex Pharmaceuticals）。根据 TipRanks 的数据，Meacham 推荐股票的平均回报率为 4.2%，成功率为 55.14%。福泰制药的分析师共识为适度买入，价格目标共识为 488.86 美元，较当前水平有 19.88% 的上涨空间。在 10 月 9 日发布的一份报告中，Evercore ISI 也维持了该股票的买入评级，价格目标为 475.00 美元

Meacham 关注医疗保健行业，重点分析如礼来公司、安进和福泰制药等股票。根据 TipRanks 的数据，Meacham 推荐股票的平均回报率为 4.2%，成功率为 55.14%。

福泰制药的分析师共识为适度买入，价格目标共识为 488.86 美元，较当前水平有 19.88% 的上涨空间。在 10 月 9 日发布的报告中，Evercore ISI 也维持了该股票的买入评级，目标价为 475.00 美元。

### Related Stocks

- [VRTX.US - 福泰制药](https://longbridge.com/zh-CN/quote/VRTX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX) and 10x Genomics (TXG) | Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX) and 10x Genomics (TXG) | [Link](https://longbridge.com/zh-CN/news/275989081.md) |
| Here's How Much $1000 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today | Vertex Pharmaceuticals (NASDAQ:VRTX) has delivered an average annual return of 17.22% over the past 15 years, outperform | [Link](https://longbridge.com/zh-CN/news/276269422.md) |
| Palvella Therapeutics (PVLA) Gets a Buy from Craig-Hallum | In a recent report, Craig-Hallum analyst Albert Lowe maintained a Buy rating on Palvella Therapeutics (PVLA) with a pric | [Link](https://longbridge.com/zh-CN/news/276240277.md) |
| BofA Maintains Stc at Buy Amid Expected Operational Catalysts | BofA Maintains Stc at Buy Amid Expected Operational Catalysts | [Link](https://longbridge.com/zh-CN/news/276232847.md) |
| Positive Report for LeonaBio (LONA) from Mizuho Securities | Mizuho Securities analyst Graig Suvannavejh upgraded LeonaBio (LONA) to a Buy with a price target of $10.00. Suvannavejh | [Link](https://longbridge.com/zh-CN/news/276278570.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。